Remix Therapeutics is a clinical-stage biotechnology company focused on RNA processing biology and precision medicines. The company describes its REMaster platform as integrating data science, AI, and automated wet-lab tools to discover and optimize small-molecule modulators of RNA processing. It states it launched in 2020 with headquarters in Watertown, Massachusetts.
Pharmaceutical companies are increasingly partnering with biotechs developing RNA-targeting small molecules, driven by advances in RNA structural biology and the success of drugs like Roche's Evrysdi. The approach aims to address "undruggable" targets while offering oral availability advantages.
Drug discovery is expanding beyond traditional protein targets to include RNA-targeting small molecules, cell surface proteins, and sequence-based AI platforms capable of screening billions of candidates across the entire genome.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06297941 |
Study of REM-422 in Patients With AML or Higher Risk MDS |
RECRUITING | PHASE1 |
| NCT06118086 |
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma |
RECRUITING | PHASE1/PHASE2 |
